HomeCompareARNA vs MO

ARNA vs MO: Dividend Comparison 2026

ARNA yields 2.00% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $55.1K in total portfolio value· pulled ahead in Year 4
10 years
ARNA
ARNA
● Live price
2.00%
Share price
$99.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.6K
Annual income
$227.64
Full ARNA calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — ARNA vs MO

📍 MO pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARNAMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARNA + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARNA pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARNA
Annual income on $10K today (after 15% tax)
$170.02/yr
After 10yr DRIP, annual income (after tax)
$193.49/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, MO beats the other by $24,429.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARNA + MO for your $10,000?

ARNA: 50%MO: 50%
100% MO50/50100% ARNA
Portfolio after 10yr
$50.2K
Annual income
$14,598.09/yr
Blended yield
29.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ARNA
Analyst Ratings
14
Buy
9
Hold
Consensus: Buy
Price Target
$94.00
-6.0% upside vs current
Range: $90.00 — $100.00
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARNA buys
0
MO buys
0
No recent congressional trades found for ARNA or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARNAMO
Forward yield2.00%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$22.6K$77.7K
Annual income after 10y$227.64$28,968.54
Total dividends collected$2.1K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$94.00$61.25

Year-by-year: ARNA vs MO ($10,000, DRIP)

YearARNA PortfolioARNA Income/yrMO PortfolioMO Income/yrGap
1$10,900$200.02$10,558$768.31+$342.00ARNA
2$11,867$203.76$11,352$1,015.87+$515.00ARNA
3$12,905$207.32$12,482$1,367.86+$423.00ARNA
4← crossover$14,019$210.70$14,103$1,883.39$84.00MO
5$15,214$213.92$16,472$2,664.91$1.3KMO
6$16,496$216.97$20,024$3,897.79$3.5KMO
7$17,871$219.86$25,537$5,933.74$7.7KMO
8$19,344$222.60$34,478$9,476.77$15.1KMO
9$20,923$225.19$49,776$16,022.63$28.9KMO
10$22,616$227.64$77,699$28,968.54$55.1KMO

ARNA vs MO: Complete Analysis 2026

ARNAStock

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Full ARNA Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ARNA vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARNA vs SCHDARNA vs JEPIARNA vs OARNA vs KOARNA vs MAINARNA vs PMARNA vs BTIARNA vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.